Compare Celsius Holdings, Inc. (CELH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Celsius Holdings, Inc.Trade

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Celsius Holdings, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Celsius Holdings, Inc. trades at $28.05 (market cap $6.89B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Celsius Holdings, Inc. is far larger — about 3.9× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

	CELH	RXRX
Market Cap	$6.89B	$1.78B
Sector	Consumer Staples	Health
52-Week High	$64.86	$6.79
52-Week Low	$23.77	$2.84
Enterprise Value	$8.68B	$1.30B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Celsius Holdings, Inc.

No Aura AI signal available yet.

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

CELH

Celsius core brand revenue drops 12% in Q2, prompting investigation over possible misleading disclosures.PRNewsWire · 1 day agoBearish Celsius Holdings seen as a prime beverage buyout target amid 39% YTD stock drop24/7 Wall Street · 2 days agoNeutral Celsius Holdings shares trade at a discount despite strong sales growth and activist pressure for leadership change.Seeking Alpha · 2 days agoBearish View details →

RXRX

Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships.Seeking Alpha · 1 day agoBearish View details →

About Celsius Holdings, Inc.

Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.